8 June 2022 - Newest treatment for lung cancer reinforces Novartis commitment to developing innovative therapies that improve outcomes for Canadians affected by advanced lung cancer.

Novartis Pharmaceuticals Canada is pleased to announce that Health Canada has granted a Notice of Compliance with conditions for Tabrecta (capmatinib) for the treatment of adult patients with locally advanced unresectable or metastatic non-small-cell lung cancer harbouring mesenchymal-epithelial transition exon 14 skipping alterations.

Read Novartis press release